Example for targeted druges in myocardial infarction is alirocumab, which is proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors. PSCK9 was discovered to be associated with elevated low-denisity lipoprotein (LDL) and adverse cardiovascular outcomes. This evidence concerns the gene PCSK9 and myocardial infarction.